Multiple non-psychiatric effects of phenothiazines: A review

European Journal of Pharmacology

Volumn 648, Issue 1-3, 2010, Pages 6-14

  Sudeshna, Gangopadhyay ^a   Parimal, Karmakar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Antipsychotic; Apoptosis; DNA double strand break (DSB); DNA repair; Phenothiazine

Indexed keywords

AMISULPRIDE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCIUM ION; CALMODULIN; CHLORPROMAZINE; CISPLATIN; FLUPHENAZINE; HEME; MESORIDAZINE; PALIPERIDONE; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; PIPERAZINE; PIPERIDINE; PRION PROTEIN; REGULATOR PROTEIN; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE;

AKATHISIA; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; BINDING AFFINITY; BIOINFORMATICS; BLURRED VISION; CALCIUM BINDING; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PAIN; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONCENTRATION RESPONSE; CONSTIPATION; CREUTZFELDT JAKOB DISEASE; DIZZINESS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DROWSINESS; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DYSTONIA; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; HICCUP; HUMAN; HYPOTENSION; IN VITRO STUDY; LUNG CANCER; MENTAL DISEASE; MILK; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; NAUSEA; NEOPLASM; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PARKINSONISM; PHARMACOGENOMICS; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PSYCHOSIS; RETINOPATHY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SCRAPIE; SEDATION; SIDE EFFECT; SLURRED SPEECH; STRUCTURE ACTIVITY RELATION; TARDIVE DYSKINESIA; TERATOGENICITY; ULTRAVIOLET IRRADIATION; URINE RETENTION; VOMITING; XEROSTOMIA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; HUMANS; PHENOTHIAZINES; PRION DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957752527     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.045     Document Type: Review

References (110)

1. Amaral L., Kristiansen J.E. Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants. Int. J. Antimicrob. Agents 2001, 18:411-417.
2. Azuine M.A., Tokuda H., Takayasu J., Enjyo F., Mukainaka T., Konoshima T., Nishino H., Kapadia G.J. Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models. Pharmacol. Res. 2004, 49:161-169.
3. Barancik M., Polekova L., Mrazova T., Breier A., Stankovicova T., Slezak J. Reversal effects of several Ca (2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp. Clin. Res. 1994, 20:13-18.
4. Belle V.H. The effect of drugs on calmodulin and its interaction with phosphodiesterase. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984, 17:557-567.
5. Bhattacharyya J., Bhattacharyya M., Chakrabarty A.S., Chaudhuri U., Poddar R.K. Interaction of chlorpromazine with myoglobin and hemoglobin. A comparative study. Biochem. Pharmacol. 1994, 47:2049-2053.
6. Bhattacharyya J., Das K.P. Interactions of chlorpromazine with milk proteins. Mol. Cell. Biochem. 2001, 221:11-15.
7. Bhattacharyya M., Chaudhuri U., Poddar R.K. Interaction of chlorpromazine with hemoglobin. Indian J. Biochem. Biophys. 1990, 27:240-244.
8. Borisy A.A., Elliott P.J., Hurst N.W., Lee M.S., Lehar J., Price E.R., Serbedzija G., Zimmermann G.R., Foley M.A., Stockwell B.R., Keith C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7977-7982.
9. Charp P.A. DNA repair in human cells: methods for the determination of calmodulin involvement. Methods Enzymol. 1987, 139:715-730.
10. Charp P.A., Regan J.D. Inhibition of DNA repair by trifluoperazine. Biochim. Biophys. Acta 1985, 824:34-39.
11. Choi J.H., Yang Y.R., Lee S.K., Kim S.H., Kim Y.H., Cha J.Y., Oh S.W., Ha J.R., Ryu S.H., Suh P.G. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann. N.Y. Acad. Sci. 2008, 1138:393-403.
12. Choi S.Y., Kim Y.H., Lee Y.K., Kim K.T. Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells. Br. J. Pharmacol. 2001, 132:411-418.
13. Crowle A.J., Douvas G.S., May M.H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 1992, 38:410-419.
14. Dasgupta A., Dastidar S.G., Shirataki Y., Motohashi N. Antibacterial activity of artificial phenothiazines and isoflavones from plants. Bioactive Heterocycles VI, Flavonoids and Anthocyanins in Plants, and Latest Bioactive heterocycles I 2008, 67-132. Springer. N. Motohashi (Ed.).
15. Dasgupta A., Mukherjee S., Chaki S., Dastidar S.G., Hendricks O., Christensen J.B., Kristiansen J.E., Amaral L. Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. Int. J. Antimicrob. Agents 2010, 35:174-176.
16. Dees C., Wade W.F., German T.L., Marsh R.F. Inactivation of the scrapie agent by ultraviolet irradiation in the presence of chlorpromazine. J. Gen. Virol. 1985, 66(Pt 4):845-849.
17. Delay J., Deniker P., Harl J.M. Therapeutic method derived from hiberno-therapy in excitation and agitation states. Ann. Med. Psychol. (Paris) 1952, 110:267-273.
18. de Mol N.J., Posthuma R.M., Mohn G.R. Induction of repairable DNA damage in Escherichia coli and interaction with DNA in vitro by the radical cation of chlorpromazine. Chem. Biol. Interact. 1983, 47:223-237.
19. Doh-ura K., Iwaki T., Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 2000, 74:4894-4897.
20. Eilam Y. Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes. Biochim. Biophys. Acta 1983, 733:242-248.
21. Enouf J., Toledano S.L. Relationship between structure of phenothiazine analogues and their activity on platelet calcium fluxes. Br. J. Pharmacol. 1984, 81:509-518.
22. Eriksson A., Yachnin J., Lewensohn R., Nilsson A. DNA-dependent protein kinase is inhibited by trifluoperazine. Biochem. Biophys. Res. Commun. 2001, 283:726-731.
23. Feinberg A.P., Snyder S.H. Phenothiazine drugs: structure-activity relationships explained by a conformation that mimics dopamine. Proc. Natl. Acad. Sci. U.S.A. 1975, 72:1899-1903.
24. Filburn C.R., Colpo F.T., Sacktor B. Mechanism of phenothiazine inhibition of Ca2+-dependent guanosine 3', 5'-(cyclic) monophosphate phosphodiesterase of brain. Mol. Pharmacol. 1979, 15:257-262.
25. Ford J.M., Prozialeck W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 1989, 35:105-115.
26. Fourrier A., Gasquet I., Allicar M.P., Bouhassira M., Lepine J.P., Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br. J. Clin. Pharmacol. 2000, 49:80-86.
27. Ganapathi R., Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 1983, 43:3696-3699.
28. Ganapathi R., Grabowski D., Schmidt H., Seshadri R., Israel M. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Biochem. Biophys. Res. Commun. 1985, 131:912-919.
29. Gangopadhyay S., Karmakar P., Dasgupta U., Chakraborty A. Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair. Mutat. Res. 2007, 633:117-125.
30. Gocke E. Review of the genotoxic properties of chlorpromazine and related phenothiazines, mutation research. Rev. Genet. Toxicol. 1996, 366:9-22.
31. Grankvist K., Bergstrom P., Henriksson R. Different effects of chlorpromazine on bleomycin- and epirubicin induced cytotoxicity. Biosci. Rep. 1990, 10:173-177.
32. Gresh N., Pullman B. A theoretical study of the binding of phenothiazine derivatives to residues 82-93 of calmodulin. Mol. Pharmacol. 1986, 29:355-362.
33. Hait W.N., Aftab D.T. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem. Pharmacol. 1992, 43:103-107.
34. Hait W.N., Lazo J.S., Chen D.L., Gallichio V.S., Filderman A.E. Antitumor and toxic effects of combination chemotherapy with bleomycin and a phenothiazine anticalmodulin agent. J. Natl Cancer Inst. 1988, 80:246-250.
35. Hait W.N., Morris S., Lazo J.S., Figlin R.J., Durivage H.J., White K., Schwartz P.E. Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine. Cancer Chemother. Pharmacol. 1989, 23:358-362.
36. Harris F., Chatfield L.K., Phoenix D.A. Phenothiazinium based photosensitisers- photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr. Drug Targets 2005, 6:615-627.
37. Hawtrey A., Joubert D., van J.P., Pieterse A., van Z.J., Ariatti M. Low concentrations of chlorpromazine and related phenothiazines stimulate gene transfer in HeLa cells via receptor-mediated endocytosis. Drug Deliv. 2002, 9:47-53.
38. Hirai H., Takeda S., Natori S., Sekimizu K. Inhibition of SV40 DNA replication in vitro by chlorpromazine. Biol. Pharm. Bull. 1993, 16:565-567.
39. Horn A.S., Snyder S.H. Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:2325-2328.
40. Hoyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., Bianchi K., Fehrenbacher N., Elling F., Rizzuto R., Mathiasen I.S., Jaattela M. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol. Cell 2007, 25:193-205.
41. Hubbard M., Bradley M., Sullivan P., Shepherd M., Forrester I. Evidence for the occurrence of calmodulin in the yeasts Candida albicans and Saccharomyces cerevisiae. FEBS Lett. 1982, 137:85-88.
42. Ikediobi O.N., Reimers M., Durinck S., Blower P.E., Futreal A.P., Stratton M.R., Weinstein J.N. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol. Cancer Ther. 2008, 7:1337-1346.
43. Iliakis G. The role of DNA double strand breaks in lonizing radiation-induced killing of eukaryotic cells. BioEssays 2005, 13:641-648.
44. Inoue S., Endo K., Suzuki H., Endo K. Anti-emetic treatment for patients with lung cancer after chemotherapy, and usefulness of prochlorperazine for psychiatric emesis. Gan To Kagaku Ryoho 2000, 27:405-411.
45. Kang U.G., Kim M.J., Suh P.G., Ryu S.H., Park J.B., Kim J.H., Kim Y.S., Lee Y.H. Inhibition of trifluoperazine-induced DNA fragmentation by cyclic AMP mediated signaling. Mol. Cells 1999, 9:596-602.
46. Kar M., Roy A., Bose T., Chakraborti A.S. Effect of glycation of hemoglobin on its interaction with trifluoperazine. Protein J. 2006, 25:202-211.
47. Karmakar P., Dasgupta U.B., Poddar R.K. Cytotoxic and genetic effects of X-irradiation of human cells in the presence of chlorpromazine. Mutat. Res. 1994, 321:159-164.
48. Karmakar P., Natarajan A.T., Poddar R.K., Dasgupta U.B. Induction of apoptosis by phenothiazine derivatives in V79 cells. Toxicol. Lett. 2001, 125:19-28.
49. Karran P. DNA double strand break repair in mammalian cells. Curr. Opin. Genet. Dev. 2000, 10:144-150.
50. Khan S.Z., Longland C.L., Michelangeli F. The effects of phenothiazines and other calmodulin antagonists on the sarcoplasmic and endoplasmic reticulum Ca2+ pumps. Biochem. Pharmacol. 2000, 60:1797-180.
51. Klohs W.D., Steinkampf R.W., Havlick M.J., Jackson R.C. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res. 1986, 46:4352-4356.
52. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9836-9841.
53. Koster T., Singh K., Zimmermann M., Gruys E. Emerging therapeutic agents for transmissible spongiform encephalopathies: a review. J. Vet. Pharmacol. Ther. 2003, 26:315-326.
54. Lazo J.S., Chen D.L., Gallicchio V.S., Hait W.N. Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells. Cancer Res. 1986, 46:2236-2240.
55. Lazo J.S., Hait W.N., Kennedy K.A., Braun I.D., Meandzija B. Enhanced bleomycin induced DNA damage and cytotoxicity with calmodulin antagonists. Mol. Pharmacol. 1985, 27:387-393.
56. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., Lee M.S., Zimmermann G.R., Borisy A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
57. Levin R.M., Weiss B. Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Mol. Pharmacol. 1977, 13:690-697.
58. Lialiaris T., Pantazaki A., Sivridis E., Mourelatos D. Chlorpromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study. Mutat. Res. 1992, 265:155-163.
59. Lieber M.R., Ma Y., Pannicke U., Schwarz K. Mechanism and regulation of human non homologous DNA end-joining. Nat. Rev. Mol. Cell Biol. 2003, 4:712-720.
60. Ljunggren B., Cohen S.R., Carter D.M., Wayne S.I. Chlorpromazine phototoxicity: growth inhibition and DNA-interaction in normal human fibroblasts. J. Invest. Dermatol. 1980, 75:253-256.
61. Lopez-Girona A., Colomer J., Pujol M.J., Bachs O., Agell N. Calmodulin regulates DNA polymerase alpha activity during proliferative activation of NRK cells. Biochem. Biophys. Res. Commun. 1992, 184:1517-1523.
62. Mazumder R., Ganguly K., Dastidar S.G., Chakrabarty A.N. Trifluoperazine: a broad spectrum bactericide especially active on staphylococci and vibrios. Int. J. Antimicrob. Agents 2001, 18:403-406.
63. Miskolci C., Labadi I., Kurihara T., Motohashi N., Molnar J. Guanine-cytosine rich regions of plasmid DNA can be the target in anti-plasmid effect of phenothiazines. Int. J. Antimicrob. Agents 2000, 14:243-247.
64. Mizushima T., Natori S., Sekimizu K. Inhibition of DNA synthesis in Meth A cells by chlorpromazine. Biol. Pharm. Bull. 1993, 16:953-955.
65. Molnar J., Pragai B., Berencsi K., Mandi Y., Foldeak S. Comparative study of antiproliferative effects of chlorpromazine, 7, 8-dioxochlorpromazine, amantadine-N mustard, rutin-N-mustard and alpha, beta and gamma interferon on K-562 cells in vitro. Acta Microbiol. Hung. 1985, 32:379-386.
66. Molnar J., Sakagami H., Motohashi N. Diverse biological activities displayed by phenothiazines, benzo[a]phenothiazines and benz[c]acridins (review). Anticancer Res. 1993, 13:1019-1025.
67. Molnar J., Schneider B. Plasmid curing and antibacterial effects of some chlorpromazine derivatives in relation to their molecule orbitals. Acta Microbiol. Acad. Sci. Hung. 1978, 25:291-298.
68. Motohashi N. Phenothiazines and calmodulin. Anticancer Res. 1991, 11:1125-1164.
69. Motohashi N., Gollapudi S.R., Emrani J., Bhattiprolu K.R. Antitumor properties of phenothiazines. Cancer Invest. 1991, 9:305-319.
70. Motohashi N., Kawase M., Saito S., Sakagami H. Antitumor potential and possible targets of phenothiazine-related compounds. Curr. Drug Targets 2000, 1:237-245.
71. Most H. Studies on the effectiveness of phenothiazine in human nematode infections. Am. J. Trop. Med. 1943, 23:459-464.
72. Onoda J.M., Nelson K.K., Taylor J.D., Honn K.V. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). Cancer Res. 1989, 49:2844-2850.
73. Ordway D., Viveiros M., Leandro C., Bettencourt R., Almeida J., Martins M., Kristiansen J.E., Molnar J., Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47:917-922.
74. Ordway D., Viveiros M., Leandro C., Jorge A.M., Molnar J., Kristiansen J.E., Amaral L. Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J. Infect. Chemother. 2002, 8:227-231.
75. Osborn M., Weber K. Damage of cellular functions by trifluoperazine, a calmodulin specific drug. Exp. Cell Res. 1980, 130:484-488.
76. Pantazaki A.A., Lialiaris T.S. A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids. Mutagenesis 1999, 14:243-248.
77. Pearson R.D., Manian A.A., Harcus J.L., Hall D., Hewlett E.L. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. Science 1982, 217:369-371.
78. Perez R.P., Handel L.M., Hamilton T.C. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. Gynecol. Oncol. 1992, 46:82-87.
79. Prozialeck W.C., Weiss B.J. Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships. Pharmacol. Exp. Ther. 1982, 222:509-516.
80. Ratnakar P., Murthy P.S. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol. Lett. 1992, 76:73-76.
81. Ratnakar P., Rao S.P., Sriramarao P., Murthy P.S. Structure-antitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int. Clin. Psychopharmacol. 1995, 10:39-43.
82. Riffell J.L., Zimmerman C., Khong A., McHardy L.M., Roberge M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle 2009, 8:3029-3042.
83. Roikhel V.M., Fokina G.I., Pogodina V.V. Influence of aminasine on experimental scrapie in mice. Acta Virol. 1984, 28:321-324.
84. Ruben L., Rasmussen H. Phenothiazines and related compounds disrupt mitochondrial energy production by a calmodulin-independent reaction. Biochim. Biophys. Acta 1981, 637:415-422.
85. 2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology (Berl) 2007, 191:793-803.
86. Sand O., Sletholt K., Gautvik K.M., Haug E. Trifluoperazine blocks calcium-dependent action potentials and inhibits hormone release from rat pituitary tumour cells. Eur. J. Pharmacol. 1982, 86:177-184.
87. Savino J.A., Evans J.F., Rabinowitz D., Auborn K.J., Carter T.H. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol. Cancer Ther. 2006, 5:556-563.
88. Schleuning M., Brumme V., Wilmanns W. Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. Anticancer Res. 1993, 13:599-602.
89. Schuster F.L., Mandel N. Phenothiazine compounds inhibit in vitro growth of pathogenic free-living amoebae. Antimicrob. Agents Chemother. 1984, 25:109-112.
90. Silverstone T. Clinically relevant differences between antipsychotic compounds. Acta Psychiatr. Scand. Suppl. 1990, 358:88-91.
91. Silverstone T., Turner P. Drug Treatment in Psychiatry 1995, 107-108. Routledge, New York, NY. fifth ed.
92. Sitges M., Talamo B.R. Sphingosine, W-7, and trifluoperazine inhibit the elevation in cytosolic calcium induced by high K+ depolarization in synaptosomes. J. Neurochem. 1993, 61:443-450.
93. Snyder R.D., McNulty J., Zairov G., Ewing D.E., Hendry L.B. The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat. Res. 2005, 578:88-99.
94. Snyder S.H., Banerjee S.P., Yamamura H.I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science 1974, 184:1243-1253.
95. Su Z., Martin R., Cox B.F., Gintant G. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J. Mol. Cell Cardiol. 2004, 36:151-160.
96. Sullivan G.F., Garcia-Welch A., White E., Lutzker S., Hait W.N. Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J. Exp. Ther. Oncol. 2002, 2:19-26.
97. Tafani M., Schito L., Anwar T., Indelicato M., Sale P., Di V.M., Morgante E., Beraldi R., Makovec F., Letari O., Caselli G., Spadafora C., Pucci B., Russo M.A. Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 2008, 4:1042-1053.
98. Tanaka T., Hidaka H. Hydrophobic regions function in calmodulin-enzyme(s) interactions. J. Biol. Chem. 1980, 255:11078-11080.
99. Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinas R., Kristal B.S., Hayden M.R., Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2602-2607.
100. Thompson A.A., Cornelius A.S., Asakura T., Horiuchi K. Comparative studies of phenothiazine derivatives for their effects on swelling of normal and sickle erythrocytes. Gen. Pharmacol. 1993, 24:999-1006.
101. Thompson L.H., Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 2001, 477:131-153.
102. van Gent D.C., Hoeijmakers J.H., Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2001, 2:196-206.
103. Viola G., Latterini L., Vedaldi D., Aloisi G.G., Dall'Acqua F., Gabellini N., Elisei F., Barbafina A. Photosensitization of DNA strand breaks by three phenothiazine derivatives. Chem. Res. Toxicol. 2003, 16:644-651.
104. Weiss B., Prozialeck W., Cimino M., Barnette M.S., Wallace T.L. Pharmacological regulation of calmodulin. Ann. N.Y. Acad. Sci. 1980, 356:319-345.
105. Wood N.C., Nugent K.M. Inhibitory effects of chlorpromazine on Candida species. Antimicrob. Agents Chemother. 1985, 27:692-694.
106. Zarnowska E.D., Mozrzymas J.W. Differential effects of chlorpromazine on ionotropic glutamate receptors in cultured rat hippocampal neurons. Neurosci. Lett. 2001, 305:53-56.
107. Zhang L., Yu J., Pan H., Hu P., Hao Y., Cai W., Zhu H., Yu A.D., Xie X., Ma D., Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19023-19028.
108. Zhu H.G., Tayeh I., Israel L., Castagna M. Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. J. Biol. Regul. Homeost. Agents 1991, 5:52-58.
109. Zimmer M., Hofmann F. Calmodulin antagonists inhibit activity of myosin light-chain kinase, independent of calmodulin. Eur. J. Biochem. 1984, 142:393-397.
110. Zirkle C.L., Kaiser C. Med. Chem. Ser. Rev. 1970, 1410. Wiley-Interscience, New York. A. Burger (Ed.).